Forest Laboratories, Inc. Files Lawsuits against Several Companies for Infringement of Savella® Patents

  Forest Laboratories, Inc. Files Lawsuits against Several Companies for
  Infringement of Savella® Patents

Business Wire

NEW YORK -- September 24, 2013

Forest Laboratories, Inc. (NYSE:FRX) and Forest Laboratories Holdings, Ltd.
(collectively, “Forest”) announced that Forest and Royalty Pharma Collection
Trust (“Royalty Pharma”) have jointly filed lawsuits in the U.S. District
Court for the District of Delaware against several companies for infringement
of U.S. Patent No. 6,602,911 (“the ‘911 patent”), U.S. Patent No. 7,888,342
(“the ‘342 patent”), and U.S. Patent No. 7,994,220 (“the ‘220 patent”), which
relate to Forest’s SAVELLA^® product. Forest licenses the ‘911 patent, the
‘342 patent, and the ‘220 patent from Royalty Pharma. The ‘911 patent expires
in January 2023, the ‘342 patent expires in November 2021, and the ‘220 patent
expires in September 2029.

The defendants named in the lawsuits include Apotex Corp., Hetero USA Inc.,
Lupin Ltd., Mylan Pharmaceuticals, Inc., Par Pharmaceuticals, Inc., Ranbaxy
Laboratories Ltd., and related companies and subsidiaries.

Forest and Royalty Pharma received notification from these companies that they
had filed Abbreviated New Drug Applications with Paragraph IV certifications
seeking approval to market generic versions of SAVELLA before the expiration
of the ‘911 patent, the ‘342 patent, and the ‘220 patent. The aforementioned
lawsuits were commenced before the expiration of forty-five days from the date
of receipt of each notification letter.

About Forest Laboratories

Forest Laboratories' (NYSE:FRX) longstanding global partnerships and track
record developing and marketing pharmaceutical products in the United States
have yielded its well-established central nervous system and cardiovascular
franchises and innovations in anti-infective, respiratory, gastrointestinal
and pain management medicine. Forest’s pipeline, the most robust in its
history, includes product candidates in all stages of development across a
wide range of therapeutic areas. The Company is headquartered in New York, NY.
To learn more, visit

Except for the historical information contained herein, this release contains
forward-looking statements within the meaning of the Private Securities
Litigation Reform Act of 1995. These statements involve a number of risks and
uncertainties, including the difficulty of predicting FDA approvals, the
acceptance and demand for new pharmaceutical products, the impact of
competitive products and pricing, the timely development and launch of new
products, and the risk factors listed from time to time in Forest
Laboratories' Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and
any subsequent SEC filings. Forest assumes no obligation to update
forward-looking statements contained in this release to reflect new
information or future events or developments.


Forest Laboratories, Inc.
Frank J. Murdolo, 1-212-224-6714
Vice President - Investor Relations
Press spacebar to pause and continue. Press esc to stop.